Literature DB >> 28496673

Angiotensin Receptor Blockers for the Prevention of Atrial Fibrillation Recurrences: Unending Hot Debate.

Turgay Celik1.   

Abstract

Entities:  

Year:  2010        PMID： 28496673      PMCID： PMC4955907          DOI： 10.4022/jafib.306

Source DB:  PubMed          Journal:  J Atr Fibrillation        ISSN： 1941-6911


× No keyword cloud information.
  10 in total

1.  Regulation of angiotensin II receptor subtypes during atrial fibrillation in humans.

Authors:  A Goette; M Arndt; C Röcken; A Spiess; T Staack; J C Geller; C Huth; S Ansorge; H U Klein; U Lendeckel
Journal:  Circulation       Date:  2000-06-13       Impact factor: 29.690

2.  Telmisartan has the strongest binding affinity to angiotensin II type 1 receptor: comparison with other angiotensin II type 1 receptor blockers.

Authors:  H Kakuta; K Sudoh; M Sasamata; S Yamagishi
Journal:  Int J Clin Pharmacol Res       Date:  2005

3.  Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis.

Authors:  Jeff S Healey; Adrian Baranchuk; Eugene Crystal; Carlos A Morillo; Michael Garfinkle; Salim Yusuf; Stuart J Connolly
Journal:  J Am Coll Cardiol       Date:  2005-06-07       Impact factor: 24.094

4.  Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation.

Authors:  H Nakashima; K Kumagai; H Urata; N Gondo; M Ideishi; K Arakawa
Journal:  Circulation       Date:  2000-06-06       Impact factor: 29.690

Review 5.  Role of angiotensin system and effects of its inhibition in atrial fibrillation: clinical and experimental evidence.

Authors:  Joachim R Ehrlich; Stefan H Hohnloser; Stanley Nattel
Journal:  Eur Heart J       Date:  2005-11-25       Impact factor: 29.983

6.  The comparative effects of telmisartan and ramipril on P-wave dispersion in hypertensive patients: a randomized clinical study.

Authors:  Turgay Celik; Atila Iyisoy; Hurkan Kursaklioglu; M Ilker Yilmaz; Sedat Kose; Selim Kilic; Basri Amasyali; Sait Demirkol; Ersoy Isik
Journal:  Clin Cardiol       Date:  2005-06       Impact factor: 2.882

7.  Telmisartan, ramipril, or both in patients at high risk for vascular events.

Authors:  Salim Yusuf; Koon K Teo; Janice Pogue; Leanne Dyal; Ingrid Copland; Helmut Schumacher; Gilles Dagenais; Peter Sleight; Craig Anderson
Journal:  N Engl J Med       Date:  2008-03-31       Impact factor: 91.245

8.  Valsartan for prevention of recurrent atrial fibrillation.

Authors:  Marcello Disertori; Roberto Latini; Simona Barlera; Maria Grazia Franzosi; Lidia Staszewsky; Aldo Pietro Maggioni; Donata Lucci; Giuseppe Di Pasquale; Gianni Tognoni
Journal:  N Engl J Med       Date:  2009-04-16       Impact factor: 91.245

9.  Prevention of recurrent lone atrial fibrillation by the angiotensin-II converting enzyme inhibitor ramipril in normotensive patients.

Authors:  Fabio Belluzzi; Laura Sernesi; Paola Preti; Francesco Salinaro; Maria Luisa Fonte; Stefano Perlini
Journal:  J Am Coll Cardiol       Date:  2009-01-06       Impact factor: 24.094

10.  Insulin-sensitizing effects of telmisartan: implications for treating insulin-resistant hypertension and cardiovascular disease.

Authors:  Harrihar A Pershadsingh; Theodore W Kurtz
Journal:  Diabetes Care       Date:  2004-04       Impact factor: 19.112
  10 in total
  1 in total

1.  Sodium-Glucose Co-Transporter Inhibitors and Atrial Fibrillation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Authors:  Arjun K Pandey; Iva Okaj; Hargun Kaur; Emilie P Belley-Cote; Jia Wang; Alireza Oraii; Alexander P Benz; Linda S B Johnson; Jack Young; Jorge A Wong; Subodh Verma; David Conen; Hertzel Gerstein; Jeff S Healey; William F McIntyre
Journal:  J Am Heart Assoc       Date:  2021-08-28       Impact factor: 5.501
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.